RT Journal Article
SR Electronic
T1 Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.02.24306607
DO 10.1101/2024.05.02.24306607
A1 Myklebust, Even Moa
A1 Schjesvold, Fredrik
A1 Frigessi, Arnoldo
A1 Leder, Kevin
A1 Foo, Jasmine
A1 Köhn-Luque, Alvaro
YR 2024
UL http://medrxiv.org/content/early/2024/05/06/2024.05.02.24306607.abstract
AB Multiple myeloma (MM) patients experience repeated cycles of treatment response and relapse, yet despite close monitoring of disease status through M protein measurements, no standard model exists for relapse prediction in MM. We investigate the feasibility of predicting relapse using a hierarchical Bayesian model of subpopulation dynamics by training and testing the model on 229 patients from the IKEMA trial.After observing between 11 and 18 treatment cycles, the model predicted relapse within six cycles with an average sensitivity between 60 and 80 %, and an average specificity between 60 and 90 %. A model of linear extrapolation is preferable when patients have been observed for less than 6 cycles, but for longer observation windows the hierarchical Bayesian model is preferred. Including available baseline and longitudinal covariate information did not improve predictive accuracy. A survival analysis showed that two model parameters separated patients into groups with significantly different PFS (p < 0.001).Statement of Significance Currently, no standard model exists for relapse prediction in multiple myeloma. A personalized model of M protein development could guide the frequency of follow-up measurements, reduce uncertainty for patients, and give clinicians more time to choose the best subsequent treatment for each patient. Furthermore, models that predict relapse are required to study the effect of changing treatment in advance of relapse rather than in response to it. Our work addresses this need by developing a hierarchical Bayesian model of subpopulation dynamics for prediction of future M protein values. We validate the model on a patient cohort treated with state-of-theart CD38 inhibitor therapy and show that it can accurately predict relapse within the next six treatment cycles, highlighting the promise of mathematical modeling in multiple myeloma and for personalized medicine in general.Declaration of Interests F.S. received honorarium from Sanofi, Janssen, BMS, Oncopeptides, Abbvie, GSK, and Pfizer. The authors declare that they have no other conflicts of interest.Competing Interest StatementF.S. received honorarium from Sanofi, Janssen, BMS, Oncopeptides, Abbvie, GSK, and Pfizer.Funding StatementE. M. Myklebust, A. Köhn-Luque, and A. Frigessi were supported by the Center for research-based-innovation BigInsight under grant 237718 by the Research Council of Norway. J. Foo and K. Leder were supported by the Fulbright US-Norway Foundation. J. Foo and K. Leder were supported by the University of Oslo-University of Minnesota Norwegian Centennial Chair Grant. J. Foo was supported by the US National Science Foundation under grant number DMS-2052465. K. Leder was supported by the US National Science Foundation under grant number CMMI-2228034. We acknowledge funding from the Research Council of Norway through projects DL: Pipeline for individually tailoring new treatments in hematological cancers (PINpOINT) under project number 294916, and INTPART-International Partnerships for Excellent Education and Research under project number 309273. The authors also acknowledge the Centre for Digital Life Norway for supporting the partner project PINpOINT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol of the IKEMA trial (NCT03275285) was approved by the Institutional Ethics Committee or independent review board for each center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe code for this project is available at https://github.com/evenmm/mm-predict-ikema. Data from the IKEMA trial (NCT03275285) can be requested through the data-sharing platform Vivli. https://search.vivli.org/studyDetails/fromSearch/42d32e57-51ce-4d54-9613-eb3f7c73d30e https://github.com/evenmm/mm-predict-ikema